When grouped by anti-PAD2 antibody status, anti-PAD2 positive people with PTLD were significantly older, but did not differ by race, sex, two-tier serologic positivity for Lyme disease, duration of illness, duration of antibiotic treatment since the onset of their Lyme disease, or diagnosis of neurologic Lyme disease during the acute infection (Table 3). This evidence concerns the gene PADI2 and Lyme disease.